Project Grant R21AI202293
Award Date 8/20/26
Completion Date 7/31/28
Dollars Obligated $241K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Berkeley, CA 94720, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases awarded $185,644 to the University of California, Berkeley on August 25, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop a high-throughput pipeline for discovering novel antimicrobial compounds produced by actinomycetes with activity against Mycobacterium tuberculosis. The research pipeline uses 3D-printed assay plates to grow rare actinomycetes in interaction pairs, a condition that triggers...
- The National Institute of Allergy and Infectious Diseases awarded the University of California, Berkeley $156,104 under the Allergy and Infectious Diseases Research program on March 9, 2026, to investigate how gut bacteria mitigate Shigella infection through bacterial culturing and gnotobiotic mouse models. The research examines the effects of various gut bacteria on Shigella growth and virulence through growth curve assays and fluorescent reporter plasmid techniques, with focus on how commensal...
- The National Institute of Allergy and Infectious Diseases, a component of the Department of Health and Human Services National Institutes of Health, awarded $120,312 to the University of California, Berkeley on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award funds research into adenosine deaminases acting on RNA (ADARs), enzymes that edit RNA to regulate gene expression and immune responses. The research aims to identify viral and host...
- The National Institute of Allergy and Infectious Diseases awarded the Regents of the University of California, doing business as University of California, Berkeley, $756,714 under Project Grant R01AI197387 on April 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award funds research investigating the interplay of protein secretion and lipid virulence factors in host immune suppression by Mycobacterium tuberculosis. The work examines two critical virulence...
- The National Institute of Allergy and Infectious Diseases awarded The Regents of the University of California, San Francisco $597,421 on July 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to support research on antimicrobial resistance monitoring in connection with azithromycin mass drug administration to children in Niger. The research leverages a large biorepository of nasopharyngeal and rectal samples collected from healthy and sick children through the...
- The National Institute of Allergy and Infectious Diseases awarded $787,945 to the Regents of the University of California, doing business as University of California, Berkeley, on June 11, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The research defines the specificity requirements and functional properties of regulatory T cells (Tregs) that maintain tolerance to the microbiota, with emphasis on RORγt+ Tregs generated during the peri-weaning period in mice...
- The National Institute of Allergy and Infectious Diseases awarded $433,125 to the Regents of the University of California at Riverside on July 20, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop genetic systems for manipulation and targeted isolation of human gut microbes. The funded research constructs novel shuttle vectors to enable genetic manipulation of cultured gut microbial species and aid in efficient isolation of slow-growing, recalcitrant...
- The National Institute of Allergy and Infectious Diseases awarded The University Corporation $147,500 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct a multi-scale study of antimicrobial peptide action in non-standard bacterial growth states. The project addresses how antimicrobial peptides (AMPs)—immune-derived molecules that kill bacteria by disrupting membranes and modulate host immune responses—perform under physiologically relevant...
- The National Institute of Allergy and Infectious Diseases awarded The Regents of the University of California, San Francisco $673,851 on August 10, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop broad-spectrum inhibitors of serine and metallo carbapenemases targeting ESKAPE pathogens. The recipient will optimize a novel family of cross-class carbapenemase inhibitors to nominate one or more development candidates ready for IND-enabling studies. The...
- The National Institute of Allergy and Infectious Diseases awarded The Regents of the University of California, doing business as University of California, Berkeley, $751,663 on April 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) for research dissecting Shigella pathogenesis in vivo using a new oral infection mouse model. The project develops and employs a genetically tractable NLRC4-deficient mouse model of shigellosis to identify key host and bacterial...